Hologic, Inc. (NASDAQ:HOLX) Holdings Decreased by Townsquare Capital LLC

Townsquare Capital LLC reduced its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 81.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,470 shares of the medical equipment provider's stock after selling 27,851 shares during the quarter. Townsquare Capital LLC's holdings in Hologic were worth $466,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. General Partner Inc. acquired a new stake in shares of Hologic during the fourth quarter worth $26,000. Venturi Wealth Management LLC lifted its position in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the period. Finally, Smithfield Trust Co increased its stake in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 400 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Stock Down 0.0 %

HOLX stock traded down $0.00 during trading on Wednesday, reaching $58.19. The stock had a trading volume of 2,387,435 shares, compared to its average volume of 1,957,164. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm has a fifty day moving average price of $61.34 and a 200 day moving average price of $70.45. The company has a market capitalization of $13.06 billion, a P/E ratio of 18.36, a PEG ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a 1-year low of $55.89 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on HOLX. Morgan Stanley decreased their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Royal Bank of Canada dropped their price objective on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. Evercore ISI reduced their target price on Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a report on Thursday, February 6th. Argus lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, Leerink Partners lowered Hologic from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.